Paul D. Burgess files SEC Form 4 disclosures for Cerevel Therapeutics Holdings, Inc.. They have made 2 open-market trades across 2 companies since 2021, most recently 2024-08-01.
CIK 0001744627
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $1.0M since 2023, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CERE | 45,727 | $2.1M |
Shares reported on the most recent Form 4, priced at the 2023-12-21 close.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.